In the afternoon of February 22, Professor Wang Jianxun, the chief scientist of our company, and Sun Rui, the deputy director of research and development department, visited Shanghai Bojin Biotechnology Co., Ltd. for exchange. Su Heng, the vice president of operation and management, and Chen Fengjiao, the process developer, warmly received and held a symposium.

Under the leadership of Su Heng, vice president of operation and management, the Shenzhen Cell Valley team visited the clean workshop of Shanghai Bojin Biology, and Su Heng gave a detailed introduction to the configuration of its clean workshop and its equipment and facilities. At the symposium, Professor Wang Jianxun, the chief scientist of Shenzhen Cell Valley, introduced the development of Shenzhen Cell Valley in the past six months, including breakthroughs in the technology of anti-virus vectors, the construction of auxiliary application platforms, and the improvement of the GMP talent training mechanism. At the same time, he took advantage of the geographical advantages of the Great Bay Region to establish in-depth cooperation with many clinical research institutions, scientific research institutions, testing institutions, uation institutions, and pharmaceutical enterprises in South China.

Su Heng, vice president, said that Shanghai Bojin Biology has relatively strong clinical research strength, while Shenzhen Cell Valley has the advantage of industrialized production of anti-virus vectors. Bojin is very willing to try to use anti-virus vectors for preclinical and clinical research. The two sides should make good use of their own advantages, strengthen the alliance, build a full-chain industry, and promote the vigorous development of the domestic cell and gene therapy industry!